$ 0 0 By Sheila Plant, PhD, MHS, RAC (US), Director, Regulatory Strategy at Cato Research Special Interest Guidances/Information Date Posted Assessing User Fees Under the Generic Drug User Fee Amendments of 2017 – Draft Guidance 01 November 2019 Chronic Hepatitis D Virus Infection: Developing Drugs for Treatment Guidance for Industry – Draft Guidance 01 November 2019 Electronic Submission of IND Safety Reports Technical Conformance Guide : Guidance for Industry – Final Guidance 30 October 2019 Providing Regulatory Submissions in Electronic Format: IND Safety Reports: Guidance for Industry – Draft Guidance 30 October 2019 Type V DMFs for CDER-Led Combination Products Using Device Constituent Parts With Electronics or Software Guidance for Industry – Draft Guidance 28 October 2019 Breast Implants – Certain Labeling Recommendations to Improve Patient Communication: Draft Draft Guidance for Industry and Food and Drug Administration Staff – Draft Guidance 24 October 2019 Drug Products Labeled as Homeopathic Guidance for FDA Staff and Industry: Draft Revised Draft – Draft Guidance 24 October 2019 Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry – Draft Guidance 24 October 2019 Identification of Manufacturing Establishments in Applications Submitted to CBER and CDER Questions and Answers – Final Guidance 22 October 2019 Drug Master Files Guidance for Industry – Draft Guidance 18 October 2019 Prescription Drug User Fee Act Waivers, Reductions, and Refunds for Drug and Biological Products Guidance for Industry – Final Guidance 16 October 2019 Submitting Study Datasets for Vaccines to the Office of Vaccines Research and Review: Guidance for Industry; Technical Specifications Document – Final Guidance 15 October 2019 Coronary, Peripheral, and Neurovascular Guidewires – Performance Tests and Recommended Labeling: Guidance for Industry and Food and Drug Administration Staff – Final Guidance 10 October 2019 Intravascular Catheters, Wires, and Delivery Systems with Lubricious Coatings – Labeling Considerations: Guidance for Industry and Food and Drug Administration Staff – Final Guidance 10 October 2019 Investigational In Vitro Diagnostics in Oncology Trials: Streamlined Submission Process for Study Risk Determination Guidance for Industry – Final Guidance 09 October 2019 Further Testing of Donations that are Reactive on a Licensed Donor Screening Test for Antibodies to Hepatitis C Virus: Guidance for Industry – Final Guidance 02 October 2019 Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment: Guidance for Industry – Final Guidance 02 October 2019 Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion: Guidance for Industry – Final Guidance 30 September 2019 Upcoming Meetings (* = New) November 6-7, 2019: General Hospital and Personal Use Devices Panel of the Medical Devices Advisory Committee Meeting November 8, 2019: Vaccines and Related Biological Products Advisory Committee Meeting November 13, 2019: Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting November 13-14, 2019: Immunology Devices Panel of the Medical Devices Advisory Committee Meeting * November 14, 2019: Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting * Blood Products Advisory Committee November 22, 2019 Meeting Last updated: 05 November 2019